St Jude Sets Sights On Year-End US Approval For NanoStim
This article was originally published in Clinica
Executive Summary
Results of the LEADLESS II trial, presented at the European Society of Cardiology Congress in London, will support a US FDA premarket approval application for St Jude’s Nanostim leadless pacemaker by the end of 2015, the company says.